Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment.

Elevated blood-based p-tau217 levels predict up to 38% risk of cognitive impairment over 10 years in unimpaired older adults.

• Why it matters: Accurate early biomarkers are essential for predicting Alzheimer’s disease progression and guiding interventions, yet absolute risk estimates across diverse populations are limited.
• What they did: The study analyzed baseline plasma p-tau217 levels in 2,684 cognitively unimpaired adults from multiple cohorts, tracking progression and cognitive decline over a median of 5.4 years.
• The result: Higher p-tau217 levels were linked to increased risk and faster decline, enabling time-specific risk estimates that could improve prognostic models and clinical trial designs.